Iron Deficiency Associated with Heart Failure

Course overview

Iron deficiency (ID) is highly prevalent among individuals with heart failure (HF), impacting 40 to 70% of patients with heart failure and serving as a significant prognostic indicator. Linked with oxidative metabolism and myocardial cell damage, ID exacerbates HF symptoms, including reduced exercise capacity, diminished quality of life, and heightened cardiovascular morbidity. This review explores the diagnosis, treatment, clinical outcomes, prognostic indicators, and forthcoming challenges associated with ID in HF patients. Crucially, addressing ID in HF is critical for enhancing prognosis, including clinical outcomes, quality of life, hospitalizations, and survival rates. While oral iron therapy shows efficacy in reducing mortality and hospitalizations, it falls short in improving exercise capacity and quality of life, often deterring patients due to adverse effects. In contrast, intravenous (IV) iron therapy demonstrates superior effectiveness in enhancing hematological parameters, and functional capacity, and reducing HF hospitalizations. Optimizing IV iron dosing based on individual patient characteristics is essential for balancing treatment efficacy and adverse effects. Emphasizing individualized approaches, with IV iron emerging as a superior option, underscores the necessity for ongoing research to refine dosing strategies and explore novel therapies. Addressing ID through tailored interventions, including oral or parenteral supplementation, is pivotal in averting complications and improving outcomes in HF patients.